Please assess the completion status of the following clinical trial:

Trial Title: Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria:~  1. Age 18 to 80 yrs at randomization~ 2. History of Type 2 Diabetes~ 3. Presence of systolic hypertension or pre-hypertension (average systolic blood pressure (SBP) ≥120 mmHg and \<180 mmHg.)~ 4. Urinary protein/creatinine ratio \>300 mg/g creatinine at screening~ 5. Hemoglobin A1C\<8%~ 6. Willing and able to give informed consent~* Exclusion Criteria:~  1. Average SBP of ≥180 mmHg or diastolic blood pressure (DBP) of ≥110 mmHg~ 2. Current symptomatic heart failure, history of New York Heart Association Class III or IV congestive heart failure, or left ventricular (LV) ejection fraction (by any method) \<25%; these patients may be harmed with withdrawal of diuretics~ 3. Serum potassium level \<3.5 or \>5.0 at screening~ 4. History of hyperkalemia in the last two years (serum K\>5.5)~ 5. Contraindication to use of hydrochlorothiazide or amiloride~ 6. Unstable angina pectoris or acute myocardial infarction (MI) in last 3 months~ 7. Known secondary causes of hypertension (HTN) (screening for these conditions will not be required)~ 8. Estimated glomerular filtration rate (GFR) \<60 mL/min/1.73m², as determined by validated estimating equations~ 9. On or expected to be on immunosuppressive therapy~ 10. Any history of solid organ transplantation~ 11. Significant dementia~ 12. Other factors likely to limit adherence during trial (eg. alcohol or substance abuse, plan to move in next year, history of non-adherence to medications, appointments and medical care, reluctance of close family members to participate in trial, lack of support from primary healthcare provider)~ 13. Participation in another investigational trial within 4 weeks of the screening visit~ 14. Arm Circumference too large or too small to allow accurate blood pressure measurement~ 15. Pregnancy or currently trying to become pregnant (although this is unlikely because of age limit~ 16. Incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Amiloride 10 mg, 20 mg, and diet (Type: EXPERIMENTAL): Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
- HCTZ 12.5 mg, 25 mg and diet (Type: ACTIVE_COMPARATOR): HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet

Based on this trial design, predict the completion outcome and termination type (if applicable).